Merck & Co., Inc. $MRK Stake Lessened by Soltis Investment Advisors LLC

Key Points

• Soltis Investment Advisors cut its Merck stake by 51.5% in the third quarter, selling 25,005 shares and retaining 23,512 shares valued at $3.42 million. Institutional investors collectively own 76.07% of Merck.
• Merck reported quarterly earnings and revenue above expectations and raised its 2026 outlook, supported by Keytruda/Qlex, WINREVAIR and newer products. Oncology pipeline advances also strengthened the company’s growth prospects.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $153.12, but investors still face longer-term Keytruda patent-cliff risks, generic-drug pressure and ongoing legal uncertainty.

Soltis Investment Advisors LLC lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 51.5% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,512 shares of the company's stock after selling 25,005 shares during the quarter. Soltis Investment Advisors LLC's holdings in Merck & Co., Inc. were worth $3,417,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of MRK. Susquehanna Fundamental Investments LLC acquired a new position in Merck & Co., Inc. in the second quarter worth about $11,470,000. Russell Investments Group Ltd. increased its holdings in Merck & Co., Inc. by 2.0% in the second quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company's stock valued at $331,931,000 after buying an additional 51,393 shares during the last quarter. Cardinal Capital Management raised its stake in Merck & Co., Inc. by 3.6% during the third quarter. Cardinal Capital Management now owns 99,742 shares of the company's stock valued at $14,578,000 after buying an additional 3,507 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Merck & Co., Inc. by 12.3% during the second quarter. The Manufacturers Life Insurance Company now owns 2,073,176 shares of the company's stock valued at $266,403,000 after buying an additional 227,589 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Merck & Co., Inc. by 7.0% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,184,340 shares of the company's stock valued at $794,577,000 after buying an additional 402,011 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Beat-and-raise results supported the stock. Merck lifted its 2026 adjusted earnings outlook, helped by better performance from Keytruda—including the newer Qlex formulation—and recently launched products. The company’s sales forecast was raised to approximately $66.8 billion-$67.3 billion. MRK Q3 earnings and sales beat estimates
• Positive Sentiment: Growth from newer products is helping offset longer-term patent concerns. WINREVAIR revenue rose sharply, reaching about $694 million, while Keytruda and Qlex sales remained resilient. Investors are looking for these products to reduce Merck’s dependence on Keytruda before its expected patent-related erosion later in the decade. Merck revenue up on Keytruda and Winrevair growth
• Positive Sentiment: Oncology pipeline news improved Merck’s growth narrative. Phase 3 data showed KEYTRUDA reduced the risk of disease progression in advanced endometrial cancer, while sacituzumab tirumotecan produced positive late-stage results and received FDA priority review. These developments could expand Merck’s future cancer franchise if approvals and commercialization succeed. Merck Phase 3 endometrial cancer data and FDA review
• Neutral Sentiment: Near-term revenue quality remains mixed. Management indicated that roughly $550 million of quarterly sales benefited from customer-purchase timing, suggesting underlying growth was closer to flat. Merck also warned of generic-drug headwinds in 2027, making pipeline execution increasingly important.
• Negative Sentiment: Patent-cliff and legal risks remain overhangs. Keytruda’s eventual loss of exclusivity remains the central long-term concern, and a law firm announced an investigation into potential securities-law violations related to an October 22 disclosure. No wrongdoing has been established.

Analyst Ratings Changes

A number of research analysts have commented on the company. Wells Fargo & Company increased their target price on Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an "overweight" rating in a report on Friday, September 4th. Berenberg Bank boosted their price target on Merck & Co., Inc. from $127.00 to $137.00 and gave the company a "hold" rating in a report on Friday, September 11th. Jefferies Financial Group upped their price target on Merck & Co., Inc. from $152.00 to $175.00 and gave the company a "buy" rating in a research report on Thursday, August 20th. TD Cowen upped their price target on Merck & Co., Inc. from $137.00 to $155.00 and gave the company a "hold" rating in a research report on Wednesday, September 23rd. Finally, Morgan Stanley reduced their price objective on Merck & Co., Inc. from $179.00 to $177.00 and set an "overweight" rating on the stock in a research note on Wednesday, October 7th. Seventeen equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $153.12.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $146.32 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a fifty-two week low of $82.01 and a fifty-two week high of $156.92. The firm has a 50-day simple moving average of $146.89 and a 200 day simple moving average of $126.49. The company has a market cap of $360.99 billion, a PE ratio of 117.05, a P/E/G ratio of 6.49 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $18.09 billion for the quarter, compared to analysts' expectations of $17.33 billion. During the same quarter last year, the company posted $2.58 earnings per share. Merck & Co., Inc.'s revenue was up 4.7% on a year-over-year basis. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 2.64 EPS for the current year.

Insider Activity at Merck & Co., Inc.

In related news, EVP David Maraldo sold 18,706 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the transaction, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. The trade was a 50.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Richard Deluca sold 20,784 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $130.43, for a total value of $2,710,857.12. Following the transaction, the executive vice president owned 134,703 shares of the company's stock, valued at $17,569,312.29. This represents a 13.37% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is owned by insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.